fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Lithium carbonate

All products: general benefit

Carbolith · DIN 00236683 · 300 mg · capsule

General benefitDormant since July 31, 2026 · checked October 5, 2026 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Carbolith · DIN 00236683 Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01 Health Canada: Dormant since 2026-07-31 · brand CARBOLITH · ATC N05AN01 LITHIUM · form Capsule · route Oral · ingredients LITHIUM CARBONATE 300 MG · company Bausch health, canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ministry pays: $0.0657 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00236683)

Source record
DIN 00236683: Carbolith Raw flags: sec3=Y Item: 281612002; group id 512; item number 1354; lccId None; manufacturer id VAL Source form: Cap; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $0.1236; ministry $0.0657 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00236683 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1327
Interchangeable products
Apo-Lithium Carbonate · DIN 02242838 · $0.0657 PMS-Lithium Carbonate · DIN 02216140 · $0.0657
Shortage status: resolved shortage (ended September 24, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00236683
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 31, 2026 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:16:12 Other Psychotropics) and how they are covered

Matched class: 28:16:12 Other Psychotropics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 28:16:12 Other Psychotropics

TRYPTOPHAN

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg, 750mg, 1g · Cap, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:16:12
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS LITHANE (lithium carbonate) is indicated for:  the treatment of acute manic episodes in patients with manic-depressive disorders. Maintenance therapy has been found useful in preventing or diminishing the frequency of subsequent relapses in bipolar manic-depressive patients (with a strong history of mania). 1.1 Pediatrics Pediatrics (<18 years of age): Health Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics). 1.2 Geriatrics Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00067512.PDF PM date: SEP 21, 2022 Source product: LITHANE; DIN 00406775; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)